William J Gradishar

  • 12659 Citations
1988 …2023

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

My clinical domain is breast cancer management. My clinical research interest focuses on the development of novel therapies for the treatment of breast cancer. Clinical trials focusing on precision medicine for defining the right therapy, for the right patient at the right time is our goal. To that end, molecular interogation of breast tumors are leading to novel trial design that will hopefully translate into better outcomes for our patients. In conjuction with the developmental therapeutics program, novel agents are being incorporated into clinical trials for patients with both early and late stage disease.

Certifications and Licenses

Internal Medicine
Medical Oncology

Training Experience

1986Residency, Michael Reese Medical Center
1990Fellowship, University of Chicago Hospitals

Education/Academic qualification

MD, University of Illinois at Chicago

… → 1982

Research interests

  • Breast Cancer
  • Chemotherapy
  • Clinical Research
  • Drug Discovery
  • Drugs (clinical pharmacology)
  • Genomic Medicine/Personalized Medicine
  • Medical Education

Fingerprint Dive into the research topics where William J Gradishar is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Research Output

Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Soliman, H., Wagner, S., Flake, D. D., Robson, M., Schwartzberg, L., Sharma, P., Magliocco, A., Kronenwett, R., Lancaster, J. M., Lanchbury, J. S., Gutin, A. & Gradishar, W., Mar 1 2020, In : Annals of surgical oncology. 27, 3, p. 765-771 7 p.

Research output: Contribution to journalArticle

Open Access
  • Open Access
  • Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer

    Shah, A. N., Flaum, L., Helenowski, I., Santa-Maria, C. A., Jain, S., Rademaker, A., Nelson, V., Tsarwhas, D., Cristofanilli, M. & Gradishar, W., Feb 13 2020, In : Journal for immunotherapy of cancer. 8, 1, e000173.

    Research output: Contribution to journalArticle

    Open Access
  • Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

    Dietz, J. R., Moran, M. S., Isakoff, S. J., Kurtzman, S. H., Willey, S. C., Burstein, H. J., Bleicher, R. J., Lyons, J. A., Sarantou, T., Baron, P. L., Stevens, R. E., Boolbol, S. K., Anderson, B. O., Shulman, L. N., Gradishar, W. J., Monticciolo, D. L., Plecha, D. M., Nelson, H. & Yao, K. A., Jan 1 2020, (Accepted/In press) In : Breast Cancer Research and Treatment. 181, 3, p. 487-497 11 p.

    Research output: Contribution to journalEditorial

    Open Access
  • Selective progesterone receptor modulators in early-stage breast cancer: A randomized, placebo-controlled phase II window-of-opportunity trial using telapristone acetate

    Lee, O., Sullivan, M. E., Xu, Y., Rogers, C., Muzzio, M., Helenowski, I., Shidfar, A., Zeng, Z., Singhal, H., Jovanovic, B., Hansen, N., Bethke, K. P., Gann, P. H., Gradishar, W., Kim, J. J., Clare, S. E. & Khan, S. A., Jan 1 2020, In : Clinical Cancer Research. 26, 1, p. 25-34 10 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations